Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence-Reference-Cited by-同舟云学术

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence

Published:2008-09 Issue:3 Volume:110 Page:374-382
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Havrilesky Laura J.,Whitehead Clark M.,Rubatt Jennifer M.,Cheek Robert L.,Groelke John,He Qin,Malinowski Douglas P.,Fischer Timothy J.,Berchuck Andrew

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference47 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J Clin,2006

2. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care;Schink;Sem Oncol,1999

3. Reactivity of a monoclonal antibody with human ovarian carcinoma;Bast;J Clin Invest,1981

4. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer;Rustin;Clin Cancer Res,2004

5. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer;Jacobs;Br J Obstet Gynaecol,1990

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cooperative amplification of Prussian blue as a signal indicator and functionalized metal-organic framework-based electrochemical biosensor for an ultrasensitive HE4 assay;Biosensors and Bioelectronics;2024-10

2. Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers;Cell Reports Medicine;2024-08

3. Monitoring and early warning of ovarian cancer using high-dimensional non-parametric EWMA control chart based on sliding window;2024-05-14

4. Smartphone-based device for rapid and single-step detection of piRNA–651 using anti-DNA:RNA hybrid antibody and enzymatic signal amplification;Analytica Chimica Acta;2024-05

5. HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial;Frontiers in Oncology;2024-01-11